Kineticos Ventures
VC Fund
Morrisville, United States
Kineticos Ventures is a VC fund in Morrisville focused on Biotechnology and Health Care. Kineticos Ventures Invests in biotechs looking to disrupt how drugs are developed, diseases are diagnosed and patients are treated. We focus on the areas of greatest medical need: Oncology, Neurosciences, and Rare Diseases. We believe that disruptive technologies such as Cell and Gene Therapy, Gene Editing, mRNA/RNAi will dramatically changehow medicine is practiced.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Kineticos Ventures invests in
Stages Kineticos Ventures invests in
Countries Kineticos Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Frank Lis
|
|||
Shailesh Maingi
|
|||
Investment Focus
Industry
- Biotechnology 6 (67%)
- Health Care 4 (44%)
- Pharmaceutical 3 (33%)
- Life Science 2 (22%)
- Medical 1 (11%)
Stage
- Series A 5 (56%)
- Series B 2 (22%)
- Venture - Series Unknown 2 (22%)
Country
- United States 5 (56%)
- United Kingdom 2 (22%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Frank Lis
President and CEO
|
President and CEO | Total investments: 3 | Find email | |
|
Shailesh Maingi
Founder & Exec Chair
|
Founder & Exec Chair | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Experic
|
Experic is a CMO and pharmaceutical supply services company, delivers advanced manufacturing, packaging, and labeling technologies. | $15M / Venture - Series Unknown / Sep 25, 2024 | |
Orthobond
|
Orthobond Corp. develops surface modification technology that can be applied to synthetic materials to produce biological responses. It offers a technology based on self-assembled monolayers of phosphonate (SAMP); and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganicimplants without the use of a biologic. The company also provides bioresistant technology to address the need of tissue integration into permanent implants; and AI-SAMP anti-infective technology that helps in preventing a range of orthopedic infections by killing bacteria as they contact the pin surface and preventing biofilm formation, pre and post-operatively. Orthobond Corp. was founded in 2003 and is based in North Brunswick, New Jersey. | Venture - Series Unknown / Sep 09, 2024 | |
EnteroBiotix
|
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $29.3M / Series B / Apr 04, 2024 | |
eXmoor Pharma
|
eXmoor Pharma is a technical and strategic consultancy specializing in cell and gene therapies (ATMPs) and biopharmaceuticals. | $35M / Series A / May 30, 2023 | |
|
Experic
|
Experic is a CMO and pharmaceutical supply services company, delivers advanced manufacturing, packaging, and labeling technologies. | $14M / Series B / Nov 30, 2022 | |
Inceptor Bio
|
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers, with a focus on novel mechanisms to improve immune cell performance in the tumor microenvironment. Inceptor Bio provides a partnership model to university research programs focused on cutting-edge therapeutic approaches for oncology. The combination of their lab andmanufacturing resources with the industry experience of their cell and gene therapy experts will advance therapeutics into the clinic with remarkable efficiency. | $37M / Series A / May 19, 2022 | |
|
EnteroBiotix
|
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $21.4M / Series A / Sep 07, 2021 | |
Kincell Bio
|
Kincell Bio collaborates with cell therapy developers by using considerable scientific experience and industry understanding. Transparency, accountability, and accuracy are essential to what makes us a reliable partner for process and analytical development, CMC assistance, and high-quality clinical cell therapy manufacturing services. | $36M / Series A | |
Clarametyx Biosciences
|
Clarametyx Biosciences is a late preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms. | Series A |
Co-Investors
East Seattle Partners
2 deals together
Harro Höfliger
2 deals together
Scottish Enterprise
2 deals together
Thairm Bio
2 deals together
1315 Capital
1 deal together
MVM Life Science Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kineticos Ventures invest in?
Kineticos Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kineticos Ventures?
Public channels for Kineticos Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kineticos Ventures?
The team at Kineticos Ventures includes Frank Lis (President and CEO) and Shailesh Maingi (Founder & Exec Chair). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
